A panel of four plasma amino acids is a promising biomarker for newly diagnosed bladder cancer

被引:3
|
作者
Liu, Zhipeng [1 ,2 ]
Teng, Chunying [1 ,4 ]
Wan, Wenting [1 ]
Wu, Fan [1 ]
Wu, Chao [1 ]
Ji, Weiping [3 ,5 ,6 ]
Shan, Yujuan [1 ,2 ]
机构
[1] Wenzhou Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Wenzhou 325035, Peoples R China
[2] Wenzhou Med Univ, Zhejiang Prov Key Lab Watershed Sci & Hlth, Wenzhou 325035, Peoples R China
[3] Wenzhou Med Univ, Quzhou Peoples Hosp, Dept Gen Surg, Quzhou Affiliated Hosp, Quzhou 325000, Zhejiang, Peoples R China
[4] Harbin Inst Technol, Sch Chem & Chem Engn, Dept Food Sci & Engn, Harbin 150001, Peoples R China
[5] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gen Surg, Wenzhou, Zhejiang, Peoples R China
[6] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Bladder cancer; Amino acid; Biomarker; Case-control study; METABOLISM;
D O I
10.1016/j.clnu.2024.05.003
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Metastasis and recurrence are the main causes of death in post-operative bladder cancer (BC), emphasizing the importance of exploring early-stage diagnostic markers. Serum biomarkers constitute a promising diagnostic approach for asymptomatic stage cancer as they are non-invasive, have high accuracy and low cost. Aims: To correlate concentrations of plasma amino acids with BC progression to assess their utility as an early-stage diagnostic. Methods: Newly diagnosed BC patients (n = 95) and normal controls (n = 96) were recruited during the period from 1 December 2018 to 30 December 2020. General and food frequency questionnaires established their basic information and dietary intake data. Venous blood samples were collected from fasting subjects and used to detect levels of plasma amino acids by liquid chromatography-mass spectrometry. Verification was performed on the GSE13507 transcriptome gene expression matrix of BC from Gene Expression Omnibus (GEO) database. Results: Eleven amino acids have been identified as altered in the plasma of newly diagnosed BC patients compared to controls (P < 0.05). Adjusted by gender, education, smoking and other factors, plasma ornithine level (OR = 0.256, 95% CI: 0.104-0.630) is a protective factor for BC, plasma levels of methionine (OR = 3.460, 95% CI: 1.384-8.651), arginine (OR = 3.851, 95% CI: 1.542-9.616), and glutamate (OR = 3.813, 95% CI: 1.543-9.419) are all risk factors for BC. ROC analysis demonstrated that the combination of plasma ornithine, methionine, arginine and glutamate could accurately diagnose BC (AUC = 0.84, 95% CI: 0.747-0.833). In addition, the mRNA level of arginase 1 was decreased (P < 0.05), while the inducible nitric oxide synthase was increased significantly, which may be linked with the disturbance of arginine metabolism in BC patients. Further analysis of GEO database confirmed the role of arginine metabolism. Conclusion: A biomarker panel containing four amino acids may provide a feasible strategy for the early diagnosis of BC. However, further validation is required through prospective studies. (c) 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
引用
收藏
页码:1599 / 1608
页数:10
相关论文
共 50 条
  • [21] THE INFLUENCE OF RACE ON OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED BLADDER CANCER
    Palacios, Diego Aguilar
    DeDeugd, Casey
    Yan, Xin
    Miyake, Makito
    Fujimoto, Kiyohide
    Rosser, Charles J.
    JOURNAL OF UROLOGY, 2014, 191 (04): : E498 - E499
  • [22] USE OF A NOVEL MRNA BIOMARKER PANEL FOR BLADDER CANCER RISK STRATIFICATION
    Shkolyar, Eugene
    Zhao, Qian
    Teslovich, Nicolas
    Sin, Mandy
    Trivedi, Dharati
    Lu, Ying
    Mach, Kathleen
    Liao, Joseph
    JOURNAL OF UROLOGY, 2020, 203 : E348 - E349
  • [23] A microRNA biomarker panel for the non-invasive detection of bladder cancer
    Urquidi, Virginia
    Netherton, Mandy
    Gomes-Giacoia, Evan
    Serie, Daniel J.
    Eckel-Passow, Jeanette
    Rosser, Charles J.
    Goodison, Steve
    ONCOTARGET, 2016, 7 (52) : 86290 - 86299
  • [24] Methylation of a Panel of MicroRNA Genes Is a Novel Biomarker for Detection of Bladder Cancer
    Shimizu, Takashi
    Suzuki, Hiromu
    Nojima, Masanori
    Kitamura, Hiroshi
    Yamamoto, Eiichiro
    Maruyama, Reo
    Ashida, Masami
    Hatahira, Tomo
    Kai, Masahiro
    Masumori, Naoya
    Tokino, Takashi
    Imai, Kohzoh
    Tsukamoto, Taiji
    Toyota, Minoru
    EUROPEAN UROLOGY, 2013, 63 (06) : 1091 - 1100
  • [25] DNA Hypermethylation of a Panel of Genes as an Urinary Biomarker for Bladder Cancer Diagnosis
    Georgopoulos, Petros
    Papaioannou, Maria
    Markopoulou, Soultana
    Fragou, Aikaterini
    Kouvatseas, George
    Apostolidis, Apostolos
    UROLOGY JOURNAL, 2022, 19 (03) : 214 - 220
  • [26] Aberrant methylation of a panel of miRNA genes as a novel biomarker of bladder cancer
    Shimizu, T.
    Suzuki, H.
    Nojima, M.
    Kitamura, H.
    Yamamoto, E.
    Imai, K.
    Masumori, N.
    Tsukamoto, T.
    Toyota, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E163 - U569
  • [27] Detection of early breast cancer beyond mammographic screening: a promising biomarker panel
    Hamann, Moritz
    Grill, Sabine
    Struck, Joachim
    Bergmann, Andreas
    Hartmann, Oliver
    Poelcher, Martin
    Kiechle, Marion
    BIOMARKERS IN MEDICINE, 2019, 13 (13) : 1107 - 1117
  • [28] Identification of a Plasma Four-microRNA Panel as Potential Noninvasive Biomarker for Osteosarcoma
    Lian, Feng
    Cui, Yong
    Zhou, Chenliang
    Gao, Kewei
    Wu, Liwen
    PLOS ONE, 2015, 10 (03):
  • [29] Plasma concentrations of arginine and related amino acids following traumatic brain injury: Proline as a promising biomarker of brain damage severity
    Louin, G.
    Neveux, N.
    Cynober, L.
    Plotkine, M.
    Marchand-Leroux, C.
    Jafarian-Tehrani, M.
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2007, 17 (02): : 91 - 97
  • [30] Editorial Comment to Should patients newly diagnosed with bladder cancer be screened for lung cancer?
    Washio, Masakazu
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (04) : 347 - 347